2-苯基-咪唑并[1,2-a]吡啶-8-羧酸 | 131862-27-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-苯基-咪唑并[1,2-a]吡啶-8-羧酸
• 英文名称: 2-phenyl-imidazo[1,2-a]pyridine-8-carboxylic acid
• 英文别名: 2-Phenylimidazo[1,2-a]pyridine-8-carboxylic acid
• CAS: 131862-27-6
• 化学式: C₁₄H₁₀N₂O₂
• mdl: MFCD09864105
• 分子量: 238.246
• InChiKey: KWBNZRKTIVPZIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(3-氯苯基)氨基]乙腈 、 2-苯基-咪唑并[1,2-a]吡啶-8-羧酸 在 碳酸氢钠 、 三氯氧磷 作用下， 以 水 、 乙腈 为溶剂， 以27.2%的产率得到α-(2-phenyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(3-chlorophenyl)acetonitrile
  参考文献：
  名称：

  Condensed heterocyclic compounds, their production and use

  摘要：

  一种具有通用式的缩合杂环化合物：##STR1## 其中Q是具有未取代或取代的桥头氮原子的缩合杂环基团，X是通过C、O、S或N连接的氢原子或基团，Y是电子亲和基团，或其盐，可用作农药。

  公开号：

  US05498774A1

文献信息

• IMIDAZO [1, 2-A] PYRROLO [3, 2-C] PYRIDINE COMPOUNDS USEFUL AS PESTIVIRUS INHIBITORS
  申请人：Neyts Johan

  公开号：US20100093781A1

  公开（公告）日：2010-04-15

  The present invention relates to a series of novel imidazo[1,2-α]pyrrolo[3,2-c]pyridines (or also named 6H-1,3a,6-Tri-aza-αy-indacenes) and derivatives thereof, according to formula: (I); The present invention also relates to processes for the preparation of imidazo[1,2-α]pyrrolo[3,2-c]pyridines, their use as. a, medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Bovine Viral Diarrhea virus (BVDV).

  本发明涉及一系列新型咪唑[1,2-α]吡咯并[3,2-c]吡啶（或称为6H-1,3a,6-三氮杂-α-吲哚烯）及其衍生物，其化学式如下：（I）；本发明还涉及制备咪唑[1,2-α]吡咯并[3,2-c]吡啶的方法，它们作为药物的用途，用于治疗或预防病毒感染以及用于制造用于治疗或预防病毒感染的药物，特别是用于感染属于黄病毒科家族的病毒，更好地用于治疗或预防感染牛病毒性腹泻病毒（BVDV）的感染。
• Heterocyclic compounds and their use as parp inhibitors
  申请人：——

  公开号：US20030134843A1

  公开（公告）日：2003-07-17

  The invention relates to compounds of formula (I), wherein; either A 1 or A 2 represents CONH 2 , and the other radical A 2 or A 1 represents hydrogen, chlorine, fluorine, bromine, iodine C 1 -C 6 alkyl, OH, nitro, CF 3 , CN, NR 11 R 12 , NH—CO—R 13 , O—C 1 -C 4 alkyl; X 1 can represent N and C—R 2 ; X 2 , independent of X 1 , can represent N and C—R 2 ; R 2 can represent hydrogen, C 1 -C 6 alkyl, C 1 -C 4 alkyl-phenyl, phenyl; B can represent an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, which can each still be substituted with an R 4 and a maximum of 3 of the same or different radicals R 5 , and; R 1 , R 4 , R 5 , R 11 -R 13 have the meanings as cited in claim No. 1. The invention also relates to the tautomeric forms, and possible enantiomeric and diastereomeric forms of said compounds, to the prodrugs thereof and to their use as PARP inhibitors.

  本发明涉及化合物的公式（I），其中：A1或A2代表CONH2，而另一个基团A2或A1代表氢，氯，氟，溴，碘，C1-C6烷基，OH，硝基，CF3，CN，NR11R12，NH-CO-R13，O-C1-C4烷基；X1可以表示N和C-R2；独立于X1的X2可以表示N和C-R2；R2可以表示氢，C1-C6烷基，C1-C4烷基苯基，苯基；B可以表示最多具有15个碳原子的不饱和，饱和或部分不饱和的单环，双环或三环环，具有最多14个碳原子和0至5个氮原子，0至2个氧原子或0至2个硫原子的不饱和，饱和或部分不饱和的单环，双环或三环环，每个仍可用R4和最多3个相同或不同的基团R5取代；R1，R4，R5，R11-R13具有权利要求1所述的含义。本发明还涉及所述化合物的互变异构体形式，可能的对映异构体和顺反异构体形式，它们的前药和它们作为PARP抑制剂的用途。
• IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B.

  公开号：US20110077248A1

  公开（公告）日：2011-03-31

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新的调节sirtuin的化合物及其使用方法。这些调节sirtuin的化合物可用于增加细胞寿命，治疗和/或预防各种疾病和障碍，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了含有调节sirtuin的化合物和另一种治疗剂的组合物。
• Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10058549B2

  公开（公告）日：2018-08-28

  rmidazo[1,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  式（Ia）的咪唑并[1,2-α]吡啶衍生物及其药物组合物，可调节 5-HT2A 血清素受体的活性。其化合物和药物组合物用于治疗失眠、失眠症、副失眠和相关睡眠障碍、血小板聚集、冠状动脉疾病、心肌梗塞、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、躁动或其症状、行为障碍、药物性精神病、兴奋性精神病、Gilles de Ia Tourette 综合征、躁狂症、器质性或非器质性精神病、精神障碍、精神病、急性精神分裂症、慢性精神分裂症、非器质性精神分裂症及相关疾病、糖尿病相关疾病、进行性多灶性白质脑病等。本发明还涉及与其他药剂单独或联合给药治疗 5-HT2A 血清素受体介导的疾病的方法。
• HETEROZYKLISCHE VERBINDUNGEN UND DEREN ANWENDUNG ALS PARP-INHIBITOREN
  申请人：Abbott GmbH & Co. KG

  公开号：EP1257551B1

  公开（公告）日：2007-09-05